english.prescrire.org > Spotlight > Archives : 2025 > Dostarlimab (Jemperli°) in advanced or recurrent endometrial cancer with DNA repair defects

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Dostarlimab (Jemperli°) in advanced or recurrent endometrial cancer with DNA repair defects

 Marketing Authorisations  Dostarlimab is an immunostimulatory anti-PD-1 antibody that has been authorised in the European Union for use in patients with advanced or recurrent mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer, either in first-line treatment in combination with carboplatin and paclitaxel, or in second-line treatment as monotherapy.
Full article available for download by subscribers

 ©Prescrire 1 February 2025

Source: "Dostarlimab (Jemperli°) in advanced or recurrent endometrial cancer with DNA repair defects" Prescrire Int 2025; 34 (267): 40-41. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook Share on  Twitter
 
 
See also:

"Lenvatinib (Lenvima°)
+ pembrolizumab (Keytruda°)
in advanced or relapsed
endometrial cancer"
Prescrire Int 2023;
32 (250): 178.
Subscribers only
 
"Pembrolizumab (Keytruda°)
as second- or subsequent-line
treatment for various cancers
with DNA repair defects"
Prescrire Int 2024;
33 (256): 44.
Subscribers only